A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease

被引：0
|
作者：
Gordon Wilcock
Ian Howe
Hilary Coles
Sean Lilienfeld
Luc Truyen
Young Zhu
Roger Bullock
Paul Kershaw
机构：
[1] University of Bristol,Department of Care of the Elderly
[2] Frenchay Hospital,Department of Old Age Psychiatry, Kingshill Research Centre
[3] Shire Pharmaceuticals,undefined
[4] Ltd.,undefined
[5] Chineham,undefined
[6] Janssen-Cilag UK,undefined
[7] Saunderton,undefined
[8] Janssen Pharmaceutica Products,undefined
[9] L.P.,undefined
[10] Johnson & Johnson Pharmaceutical Research & Development,undefined
[11] LLC,undefined
[12] Victoria Hospital,undefined
来源：
Drugs & Aging | 2003年 / 20卷
关键词：
MMSE Score; Galantamine; Caregiver Burden; Neuronal Nicotinic Receptor; Baseline MMSE Score;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：777 / 789
页数：12
相关论文
共 50 条
  • [21] Alzheimer's disease -: Safety and dropout in long-term galantamine treatment in a routine clinical setting
    Wallin, A. K.
    Wattmo, C.
    Minthon, L.
    NEW TRENDS IN ALZHEIMER AND PARKINSON RELATED DISORDERS: ADPD 2007, 2007, : 245 - 249
  • [22] Galantamine, a novel treatment for Alzheimer's disease: A review of long-term benefits to patients and caregivers
    Tariot, P
    Winblad, B
    ALZHEIMER'S DISEASE: ADVANCES IN ETIOLOGY, PATHOGENESIS AND THERAPEUTICS, 2001, : 707 - 723
  • [23] Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting
    Wallin, Asa K.
    Wattmo, Carina
    Minthon, Lennart
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 565 - 576
  • [24] Effect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia
    Droogsma, E.
    Van Asselt, D. Z. B.
    Van Steijn, J. H. M.
    Schuur, T.
    Huinink, E. J.
    JOURNAL OF NUTRITION HEALTH & AGING, 2013, 17 (05): : 461 - 465
  • [25] Effect of long-term treatment with galantamine on weight of patients with Alzheimer’s dementia
    E. Droogsma
    D. Z. B. Van Asselt
    J. H. M. Van Steijn
    T. Schuur
    E. J. Huinink
    The journal of nutrition, health & aging, 2013, 17 : 461 - 465
  • [26] Long-term treatment with galantamine is effective in patients with Alzheimer's disease for up to 3 years.
    Raskind, MA
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2002, 50 (04) : S64 - S65
  • [27] Long-term treatment with galantamine of patients with Alzheimer's disease leads to a broad spectrum of beneficial effects
    Schmitt, A
    Schreiner, A
    Hager, K
    NEUROBIOLOGY OF AGING, 2004, 25 : S195 - S195
  • [28] Galantamine in advanced moderate Alzheimer's disease: Long-term benefits and the effect of delayed initiation of treatment
    Blesa, R
    van Baelen, B
    Kavanagh, S
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S334 - S334
  • [29] Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease
    Kurz, AF
    Erkinjuntti, T
    Small, GW
    Lilienfeld, S
    Damaraju, CRV
    EUROPEAN JOURNAL OF NEUROLOGY, 2003, 10 (06) : 633 - 640
  • [30] Galantamine produces long-term cognitive benefit's in patients with Alzheimer's disease.
    Tariot, PN
    Kershaw, P
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2002, 10 (02): : 93 - 94
12345